Abaloparatide 3mg

• Significant Fracture Reduction: Studies demonstrated that abaloparatide reduced the risk of new vertebral (spine) fractures by 88% and non-vertebral fractures by 69% compared to a placebo.
• Increased Bone Density: It acts as a parathyroid hormone-related peptide (PTHrP) analog, actively stimulating bone formation to increase density in the hip and spine.
• Targeted Treatment for High Risk: It is approved for postmenopausal women and men with osteoporosis at high risk of fracture, including those who have already experienced a fracture.
• Effective Alternative: It is considered as effective as other anabolic treatments (like teriparatide) and can be used to treat patients who have failed or cannot tolerate other osteoporosis therapies.
• Clinical Efficacy: When followed by an anti-resorptive treatment (like alendronic acid), it resulted in an 84% lower risk of new vertebral fractures compared to placebo.
• Reduced Hypercalcemia Risk: Compared to teriparatide, abaloparatide showed a 51% lower prevalence of hypercalcemia (excess calcium in the blood), which is a potential side effect of some bone-building drugs. 

Chemical Information

• Synonyms: BA 058; BIM 44058
• CAS Number: 247062-33-5
• Molecular Formula: C₁₇₄H₃₀₀N₅₆O₄₉
• Form: Lyophilized powder, 10mg per vial
• Purity: ≥99% (Peptide-grade)
• Storage: Store at 2–8°C, protected from light and moisture

Product Assurance

✅ HPLC Verified – Ensuring ≥99% purity
✅ COA Provided – On Request
✅ Manufactured in a GMP-Certified Facility - Developed & Dispatched in the UK
✅ Third-Party Testing Covered – Independent Verification Available on Request
✅ Cold Chain Express Delivery – Ensuring Potency, Integrity & Safe Arrival